{"entity":{"id":"five-prime-therapeutics","kind":"company","name":"Five Prime Therapeutics","aka":["Five Prime Therapeutics, Inc.","Five Prime","NASDAQ:FPRX"],"tldr":"Five Prime Therapeutics developed bemarituzumab, an antibody aimed at a protein called FGFR2b that some stomach cancers carry in large amounts. Amgen bought the company in 2021.","summary":"Five Prime Therapeutics, Inc. (formerly Nasdaq: FPRX), of South San Francisco, was a clinical-stage company developing immuno-oncology and targeted cancer therapies. Its lead asset, bemarituzumab, is an antibody against FGFR2b, which the announcement says is overexpressed in about 30% of people with HER2-negative gastric cancer; the randomised, placebo-controlled phase 2 FIGHT trial in first-line advanced gastric or gastro-oesophageal junction cancer reported improvements in progression-free survival, overall survival and response rate. Amgen agreed on 4 March 2021 to buy Five Prime for USD 38 per share in cash, an equity value of about USD 1.9 billion, and the merger was completed on 16 April 2021.","asOf":"2026-11-03","links":[{"label":"Amgen to acquire Five Prime Therapeutics (8-K exhibit 99.1, 4 March 2021)","url":"https://www.sec.gov/Archives/edgar/data/1175505/000119312521068593/d77427dex991.htm"},{"label":"Form 8-K: completion of the merger (16 April 2021)","url":"https://www.sec.gov/Archives/edgar/data/1175505/000119312521118566/d153048d8k.htm"}],"tags":[],"related":[],"cancers":["gastric"],"sections":["targeted-therapy","immunotherapy"],"technologies":["monoclonal-antibody"],"targets":["fgfr2"],"drugs":["bemarituzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Completion on 16 April 2021 is from Five Prime's 8-K of that date. No website or founding year is recorded."],"hq":"South San Francisco, CA","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2021,"amountUsd":1900000000,"source":"https://www.sec.gov/Archives/edgar/data/1175505/000119312521068593/d77427dex991.htm","note":"Amgen's announcement of 4 March 2021, filed as exhibit 99.1 to Five Prime's 8-K: USD 38.00 per share in cash, equity value of approximately USD 1.9 billion"}],"acquiredBy":"amgen"},"route":"/companies/five-prime-therapeutics/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"}],"drug":[{"id":"bemarituzumab","kind":"drug","name":"Bemarituzumab","route":"/drugs/bemarituzumab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}]}}